NEW YORK --(BUSINESS WIRE)

If you have suffered a loss on your Marex Group PLC (“Marex” or the “Company”) (NASDAQ:MRX) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until December 8, 2025 to ask the Court to appoint them as lead plaintiff.

What Happened?

On August 5, 2025, NINGI Research published a report alleging, among other things, that Marex “has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure.” The report alleged, among other things, that the Company has “numerous multi-million-dollar discrepancies in intercompany receivables and loans across Marex’s sprawling network of 56+ entities.” The report identified examples, including “a $17 million receivable created out of thin air, a subsidiary whose reported profit was inflated by 150% in group filings before being liquidated, and an asset valued at $14.9 million that was sold to Robinhood for just $2.5 million weeks later, with no reported loss.” The report further alleged the Company concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund it both controls and trades with, and that it is using the fund to generate non-cash trading profits and inflate operating cash flow by misclassifying structured note issuance as income. On this news, the price of Marex shares declined by $2.33 per share, or approximately 6.2%, from $37.64 per share on August 4, 2025 to close at $35.31 on August 5, 2025.

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of May 16, 2024 through August 5, 2025, inclusive (“the Class Period”). The lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; and (3) as a result of the foregoing, Marex’s financial statements could not be relied upon.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1171
https://www.kmllp.com
[email protected]

Copyright Business Wire 2025

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]